Indaptus Therapeutics
INDP
14 hedge funds and large institutions have $4.24M invested in Indaptus Therapeutics in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.
149% more capital inflows, than outflows
Capital inflows: $5.54M | Capital outflows: $2.22M
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
40% more funds holding
Funds holding: 10 → 14 (+4)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
7.17% less ownership
Funds ownership: 13.79% → 6.61% (-7.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$3.94M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$782K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$283K |
| 4 |
Investment House LLC
Redondo Beach,
California
|
+$264K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$132K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AdvisorShares Investments
Bethesda,
Maryland
|
-$1.54M |
| 2 |
Meitav Investment House
Bene-Beraq,
Israel
|
-$420K |
| 3 |
GSA Capital Partners
London,
United Kingdom
|
-$116K |
| 4 |
Morgan Stanley
New York
|
-$84K |
| 5 |
Squarepoint
New York
|
-$67K |
INDP Hedge Fund Activity: Q3 2021 in Review
14 of the 5,730 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q3 2021, worth a combined $4.24M — up 84% from $2.31M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new INDP positions and 4 closed out — a net gain of 4 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.94M. The largest seller was AdvisorShares Investments, exiting entirely with an estimated $1.54M sold.
- 14 institutional investors held Indaptus Therapeutics (INDP) as of Q3 2021, up from 10 in Q2 2021.
- Funds reported $4.24M of Indaptus Therapeutics stock for Q3 2021, up 84% quarter-over-quarter.
- 8 funds opened new Indaptus Therapeutics positions in Q3 2021 and 4 closed out, a net change of +4 holders.
- The largest Indaptus Therapeutics buyer in Q3 2021 was Armistice Capital, an estimated $3.94M added.
- The largest Indaptus Therapeutics seller in Q3 2021 was AdvisorShares Investments, an estimated $1.54M sold.
Based on aggregated 13F filings for Q3 2021.